Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription 19.09.2022 1 Ann Surg 31 Ann Surg Oncol 2 BMC Cancer 3 Br J Cancer 1 Breast Cancer (Auckl) 1 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 12 Breast Cancer Res Treat 2 Breast J 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 1 Clin Breast Cancer 1 Clin Cancer Res 4 Eur Radiol 1 Gene 1 Histopathology 1 J Surg Oncol 1 NPJ Breast Cancer 1 Oncogene 1 Oncology 5 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg

1. SCHUMACHER JR, Lawson EH, Kong AL, Weber JJ, et al
   A Statewide Approach to Reducing Re-excision Rates for Women With Breast-conserving Surgery.
   Ann Surg. 2022;276:665-672.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. CRARY IL, Flanagan MR
   ASO Author Reflections: Is Surgical Excision Necessary in Lobular Neoplasia with Synchronous Breast Carcinoma?
   Ann Surg Oncol. 2022;29:6359.
   PubMed        
   
   
3. ZHANG C, Kosiorek HE, Patel BK, Pockaj BA, et al
   Accuracy of Posttreatment Imaging for Evaluation of Residual in Breast Disease After Neoadjuvant Endocrine Therapy.
   Ann Surg Oncol. 2022;29:6207-6212.
   PubMed         Abstract available
   
   
4. SANDERS SB, Hoskin TL, Solanki MH, Stafford AP, et al
   Lack of Clinical Value for Immunohistochemistry for Sentinel Lymph Node Assessment in Invasive Lobular Carcinoma.
   Ann Surg Oncol. 2022;29:6458-6465.
   PubMed         Abstract available
   
   
5. DIEGO EJ, Rosenberger LH, Deng X, McGuire KP, et al
   Margin Management and Adjuvant Therapy for Phyllodes Tumors: Practice Patterns of the American Society of Breast Surgeons Members.
   Ann Surg Oncol. 2022;29:6151-6161.
   PubMed         Abstract available
   
   
6. A DE LA CRUZ-KU G, Karamchandani M, Chambergo-Michilot D, Narvaez-Rojas AR, et al
   ASO Visual Abstract: Does Breast-Conserving Surgery with Radiotherapy Have a Better Survival Than Mastectomy? A Meta-Analysis of More Than 1,500,000 Patients.
   Ann Surg Oncol. 2022;29:6197-6198.
   PubMed        
   
   
7. ABUJBARAH SM, Jogerst K, Kosiorek HE, Ahmad S, et al
   Postoperative Hematomas in the Era of Outpatient Mastectomy: Is Ketorolac Really to Blame?
   Ann Surg Oncol. 2022;29:6395-6403.
   PubMed         Abstract available
   
   
8. ROBBINS T, Hoskin TL, Day CN, Mrdutt MM, et al
   Node Positivity Among Sonographically Suspicious but FNA-Negative Axillary Nodes.
   Ann Surg Oncol. 2022;29:6276-6287.
   PubMed         Abstract available
   
   
9. TELLER P, Nguyen TT, Tseng J, Allen L, et al
   Innovation in Breast Surgery: Practical and Ethical Considerations.
   Ann Surg Oncol. 2022;29:6144-6150.
   PubMed         Abstract available
   
   
10. CRARY IL, Parker EU, Lowry KP, Patwardhan PP, et al
    ASO Visual Abstract: Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma.
    Ann Surg Oncol. 2022;29:6360.
    PubMed        
    
    
11. SANDERS SB, Hoskin TL, Solanki MH, Stafford AP, et al
    ASO Visual Abstract: Lack of Clinical Value for Immunohistochemistry for Sentinel Lymph Node Assessment in Invasive Lobular Carcinoma.
    Ann Surg Oncol. 2022;29:6468.
    PubMed        
    
    
12. DE LA CRUZ KU G, Karamchandani M, Chambergo-Michilot D, Narvaez-Rojas AR, et al
    Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients.
    Ann Surg Oncol. 2022;29:6163-6188.
    PubMed         Abstract available
    
    
13. SATTAR AK, Shahzad H, Masroor T, Martins RS, et al
    Practice Patterns of Antibiotic Prophylaxis in Patients Undergoing Mastectomy: A Survey of Members of the American Society of Breast Surgeons.
    Ann Surg Oncol. 2022;29:6314-6322.
    PubMed         Abstract available
    
    
14. CHAKEDIS JM, Tang A, Savitz A, Lyon LL, et al
    Economic Impact of Reducing Reexcision Rates after Breast-Conserving Surgery in a Large, Integrated Health System.
    Ann Surg Oncol. 2022;29:6288-6296.
    PubMed         Abstract available
    
    
15. SATTAR AK, Shahzad H, Masroor T, Martins RS, et al
    ASO Visual Abstract: Practice Patterns of Antibiotic Prophylaxis in Patients Undergoing Mastectomy-A Survey of Members of the American Society of Breast Surgeons.
    Ann Surg Oncol. 2022;29:6325-6326.
    PubMed        
    
    
16. DIEGO EJ, Rosenberger LH, Deng X, McGuire KP, et al
    ASO Visual Abstract: Margin Management and Adjuvant Therapy for Phyllodes Tumors-Practice Patterns of the American Society of Breast Surgeons Members.
    Ann Surg Oncol. 2022;29:6162.
    PubMed        
    
    
17. MARTINS RS, Sattar AK
    ASO Author Reflections: Perioperative Antibiotic Prophylaxis for Mastectomy-Too Much or Too Little.
    Ann Surg Oncol. 2022;29:6323-6324.
    PubMed        
    
    
18. OROZCO JIJ, Le J, Baker JL, Marzese DM, et al
    ASO Author Reflections: Molecular Signatures May Render Surgical Staging of the Axilla Obsolete.
    Ann Surg Oncol. 2022;29:6415-6416.
    PubMed        
    
    
19. HIEKEN TJ, Solanki MH
    ASO Author Reflections: Standardizing Pathology Examination of Sentinel Lymph Nodes in Invasive Lobular Carcinoma: Less Is More.
    Ann Surg Oncol. 2022;29:6466-6467.
    PubMed        
    
    
20. JOGERST KM, Abujbarah SM, Pockaj B
    ASO Author Reflections: Weighing the Risks and Benefits of Multimodal Analgesia Following Breast Surgery.
    Ann Surg Oncol. 2022;29:6404-6405.
    PubMed        
    
    
21. MILLER KN, Thomas SM, Sergesketter AR, Rosenberger LH, et al
    The Influence of Body Mass Index on the Histopathology and Outcomes of Patients Diagnosed with Atypical Breast Lesions.
    Ann Surg Oncol. 2022;29:6484-6494.
    PubMed         Abstract available
    
    
22. MONTAGNA G, Morrow M
    ASO Author Reflections: Do We Need to Clip Metastatic Lymph Nodes at Diagnosis and Localize Them After Neoadjuvant Chemotherapy?
    Ann Surg Oncol. 2022;29:6140-6141.
    PubMed        
    
    
23. NANDA AD, Reifel KR, Mann MP, Lyman-Hager MM, et al
    Text-Based Intervention Increases Mammography Uptake at an Urban Safety-Net Hospital.
    Ann Surg Oncol. 2022;29:6199-6205.
    PubMed         Abstract available
    
    
24. MARTINEZ EO, Jorns JM, Kong AL, Kijak J, et al
    ASO Visual Abstract: Primary Breast Neuroendocrine Tumors-An Analysis of the National Cancer Database.
    Ann Surg Oncol. 2022;29:6349.
    PubMed        
    
    
25. ABUJBARAH S, Jogerst K, Kosiorek HE, Ahmad S, et al
    ASO Visual Abstract: Postoperative Hematomas in the Era of Outpatient Mastectomy: Is Ketorolac Really to Blame?
    Ann Surg Oncol. 2022;29:6406.
    PubMed        
    
    
26. CHAKEDIS JM, Tang A, Savitz A, Lyon LL, et al
    ASO Visual Abstract: Economic Impact of Reducing Re-excision Rates After Breast-Conserving Surgery in a Large, Integrated Health System.
    Ann Surg Oncol. 2022;29:6297-6298.
    PubMed        
    
    
27. HASSAN AM, Nguyen HT, Corkum JP, Liu J, et al
    Area Deprivation Index is Associated with Variation in Quality of Life and Psychosocial Well-being Following Breast Cancer Surgery.
    Ann Surg Oncol. 2022 Sep 9. pii: 10.1245/s10434-022-12506.
    PubMed         Abstract available
    
    
28. MURPHY BL, Yi M, Gutierrez Barrera AM, Tripathy D, et al
    Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing.
    Ann Surg Oncol. 2022 Sep 12. pii: 10.1245/s10434-022-12468.
    PubMed         Abstract available
    
    
29. SROUR MK, Tadros AB, Sevilimedu V, Nelson JA, et al
    ASO Visual Abstract: Who Are We Missing: Does Engagement in Patient-Reported Outcome Measures for Breast Cancer Vary by Age, Race, and Disease Stage?
    Ann Surg Oncol. 2022 Sep 13. pii: 10.1245/s10434-022-12511.
    PubMed        
    
    
30. GENTLE CK, Pratt DA
    ASO Author Reflections: It is Time to Deescalate Screening Mammography for Patients Who Do Not Benefit.
    Ann Surg Oncol. 2022;29:6367-6368.
    PubMed        
    
    
31. CRARY IL, Parker EU, Lowry KP, Patwardhan PP, et al
    Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma.
    Ann Surg Oncol. 2022;29:6350-6358.
    PubMed         Abstract available
    
    
32. MARTINEZ EO, Jorns JM, Kong AL, Kijak J, et al
    Primary Breast Neuroendocrine Tumors: An Analysis of the National Cancer Database.
    Ann Surg Oncol. 2022;29:6339-6346.
    PubMed         Abstract available
    
    

    
    BMC Cancer

33. AL SAAD S, Al Shenawi H, Almarabheh A, Al Shenawi N, et al
    Is laterality in breast Cancer still worth studying? Local experience in Bahrain.
    BMC Cancer. 2022;22:968.
    PubMed         Abstract available
    
    
34. MCCLELLAN B, Gries P, Harlow B, Tiziani S, et al
    An IGF-1R-mTORC1-SRPK2 signaling Axis contributes to FASN regulation in breast cancer.
    BMC Cancer. 2022;22:976.
    PubMed         Abstract available
    
    

    
    Br J Cancer

35. STANNARD R, Lambert PC, Andersson TM, Rutherford MJ, et al
    Obtaining long-term stage-specific relative survival estimates in the presence of incomplete historical stage information.
    Br J Cancer. 2022;127:1061-1068.
    PubMed         Abstract available
    
    
36. FERNANDEZ-GARCIA D, Nteliopoulos G, Hastings RK, Rushton A, et al
    Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
    Br J Cancer. 2022 Sep 10. pii: 10.1038/s41416-022-01962.
    PubMed         Abstract available
    
    
37. FALLOWFIELD L, Solis-Trapala I, Starkings R, May S, et al
    Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing.
    Br J Cancer. 2022;127:1116-1122.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

38. KESHAVARZI A, Asadi S, Asadollahi A, Mohammadkhah F, et al
    Tendency to Breast Cancer Screening Among Rural Women in Southern Iran: A Structural Equation Modeling (SEM) Analysis of Theory of Planned Behavior.
    Breast Cancer (Auckl). 2022;16:11782234221121001.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

39. XIA J, Wang Q, Ju F, Luo X, et al
    Chloride Intracellular Channel 1 is a Potential Biomarker for Breast Cancer.
    Breast Cancer (Dove Med Press). 2022;14:247-258.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

40. LOUDIG O, Mitchell MI, Ben-Dov IZ, Liu C, et al
    MiRNA expression deregulation correlates with the Oncotype DX((R)) DCIS score.
    Breast Cancer Res. 2022;24:62.
    PubMed         Abstract available
    
    
41. LI C, Yoshimura T, Tian M, Wang Y, et al
    Exosomal Wnt7a from a low metastatic subclone promotes lung metastasis of a highly metastatic subclone in the murine 4t1 breast cancer.
    Breast Cancer Res. 2022;24:60.
    PubMed         Abstract available
    
    
42. LOPEZ-KNOWLES E, Detre S, Hills M, Schuster EF, et al
    Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
    Breast Cancer Res. 2022;24:61.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

43. RASK G, Nazemroaya A, Jansson M, Wadsten C, et al
    Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study.
    Breast Cancer Res Treat. 2022;195:367-377.
    PubMed         Abstract available
    
    
44. JOBSEN JJ, Struikmans H, Siemerink E, van der Palen J, et al
    The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.
    Breast Cancer Res Treat. 2022;195:249-262.
    PubMed         Abstract available
    
    
45. STANKOWSKI TJ, Schumacher JR, Hanlon BM, Tucholka JL, et al
    Barriers to breast reconstruction for socioeconomically disadvantaged women.
    Breast Cancer Res Treat. 2022;195:413-419.
    PubMed         Abstract available
    
    
46. SWARNKAR P, Mokbel L, Mokbel K
    De-escalation of breast cancer treatment for Her2-positive breast cancer.
    Breast Cancer Res Treat. 2022 Sep 9. pii: 10.1007/s10549-022-06737.
    PubMed        
    
    
47. NGUYEN THN, Nguyen TTN, Nguyen TTM, Nguyen LHM, et al
    Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2022 Sep 9. pii: 10.1007/s10549-022-06728.
    PubMed         Abstract available
    
    
48. GUNDA A, Eshwaraiah MS, Gangappa K, Kaur T, et al
    A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06729.
    PubMed         Abstract available
    
    
49. GREMKE N, Griewing S, Kalder M, Kostev K, et al
    Positive association between body height and breast cancer prevalence: a retrospective study with 135,741 women in Germany.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06730.
    PubMed         Abstract available
    
    
50. WATANABE H, Nakagomi H, Hirotsu Y, Amemiya K, et al
    TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06731.
    PubMed         Abstract available
    
    
51. CHEN M, Li S, Huang M, Guo J, et al
    Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2022 Sep 13. pii: 10.1007/s10549-022-06707.
    PubMed         Abstract available
    
    
52. THILL M, Wimberger P, Grafe A, Klare P, et al
    Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).
    Breast Cancer Res Treat. 2022 Sep 12. pii: 10.1007/s10549-022-06710.
    PubMed         Abstract available
    
    
53. ALTUNDAG K
    Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06742.
    PubMed        
    
    
54. SMITH CEP, Marcom PK, Mitri Z, Ko NY, et al
    Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions.
    Breast Cancer Res Treat. 2022 Sep 10. pii: 10.1007/s10549-022-06718.
    PubMed         Abstract available
    
    

    
    Breast J

55. YU T, Cheng W, Wang T, Chen Z, et al
    Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study.
    Breast J. 2022;2022:5325556.
    PubMed         Abstract available
    
    
56. ZHU S
    Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer.
    Breast J. 2022;2022:5049445.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

57. YE H, Tang LY, Liang ZZ, Chen QX, et al
    Effects of infection-induced fever and the interaction with interleukin-6 rs1800796 polymorphism on the prognosis of breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2022 Sep 9. pii: 709164.
    PubMed         Abstract available
    
    

    
    Cancer Lett

58. LI T, Zhai D, Zhang M, Ye R, et al
    KIF17 maintains the epithelial phenotype of breast cancer cells and curbs tumour metastasis.
    Cancer Lett. 2022 Sep 8:215904. doi: 10.1016/j.canlet.2022.215904.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

59. SHAH S, Shaing C, Khatib J, Lodrigues W, et al
    The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience.
    Clin Breast Cancer. 2022 Aug 11. pii: S1526-8209(22)00179.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

60. SHARMA P
    Time to optimize de-escalation strategies in triple-negative breast cancer?
    Clin Cancer Res. 2022 Sep 9. pii: 709144. doi: 10.1158/1078-0432.CCR-22-2140.
    PubMed         Abstract available
    
    

    
    Eur Radiol

61. LO GULLO R, Sevilimedu V, Baltzer P, Le Bihan D, et al
    A survey by the European Society of Breast Imaging on the implementation of breast diffusion-weighted imaging in clinical practice.
    Eur Radiol. 2022 May 4. pii: 10.1007/s00330-022-08833.
    PubMed         Abstract available
    
    
62. CHEN ZW, Zhao YF, Liu HR, Zhou JJ, et al
    Assessment of breast lesions by the Kaiser score for differential diagnosis on MRI: the added value of ADC and machine learning modeling.
    Eur Radiol. 2022 Jun 21. pii: 10.1007/s00330-022-08899.
    PubMed         Abstract available
    
    
63. YOON J, Lee HS, Kim MJ, Park VY, et al
    AI-CAD for differentiating lesions presenting as calcifications only on mammography: outcome analysis incorporating the ACR BI-RADS descriptors for calcifications.
    Eur Radiol. 2022 Jun 24. pii: 10.1007/s00330-022-08961.
    PubMed         Abstract available
    
    
64. POTSCH N, Korajac A, Stelzer P, Kapetas P, et al
    Breast MRI: does a clinical decision algorithm outweigh reader experience?
    Eur Radiol. 2022 Jul 19. pii: 10.1007/s00330-022-09015.
    PubMed         Abstract available
    
    

    
    Gene

65. VOUTSADAKIS IA
    Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors.
    Gene. 2022 Sep 10:146881. doi: 10.1016/j.gene.2022.146881.
    PubMed         Abstract available
    
    

    
    Histopathology

66. FOX SB, Webster F, Chen CJ, Chua B, et al
    Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2022;81:467-476.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

67. DOWNS-CANNER S, Cody HS 3rd
    Five decades of progress in surgical oncology: Breast.
    J Surg Oncol. 2022;126:852-859.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

68. MITIN N, Nyrop KA, Strum SL, Knecht A, et al
    A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer.
    NPJ Breast Cancer. 2022;8:103.
    PubMed         Abstract available
    
    

    
    Oncogene

69. LI Y, Deng Y, Zhao Y, Zhang W, et al
    Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02459.
    PubMed         Abstract available
    
    

    
    Oncology

70. SAWA A, Bando H, Kamohara R, Takeuchi N, et al
    Absolute lymphocyte count (ALC) as an independent prognostic factor in metastatic breast cancer: a retrospective study.
    Oncology. 2022 Sep 13. pii: 000526963. doi: 10.1159/000526963.
    PubMed         Abstract available
    
    

    
    PLoS One

71. LEE C, Kim S, Woo J
    A comparative analysis of factors influencing colorectal cancer's age standardized mortality ratio among Korean women in the hot and cold spots.
    PLoS One. 2022;17:e0273995.
    PubMed         Abstract available
    
    
72. STAAF J, Aine M
    Tumor purity adjusted beta values improve biological interpretability of high-dimensional DNA methylation data.
    PLoS One. 2022;17:e0265557.
    PubMed         Abstract available
    
    
73. AL-SANEA MM, Chilingaryan G, Abelyan N, Mamikonyan M, et al
    Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors.
    PLoS One. 2022;17:e0272065.
    PubMed         Abstract available
    
    
74. MIGHRI N, Mejri N, Boujemaa M, Berrazega Y, et al
    Association between epidemiological and clinico-pathological features of breast cancer with prognosis, family history, Ki-67 proliferation index and survival in Tunisian breast cancer patients.
    PLoS One. 2022;17:e0269732.
    PubMed         Abstract available
    
    
75. MEYER SB, Lunnay B, Warin M, Foley K, et al
    Examining social class as it relates to heuristics women use to determine the trustworthiness of information regarding the link between alcohol and breast cancer risk.
    PLoS One. 2022;17:e0270936.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

76. KUMAR S, Das S, Sun J, Huang Y, et al
    Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2(+) breast cancer by ceramide-loaded nanoparticles.
    Proc Natl Acad Sci U S A. 2022;119:e2205454119.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: